NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00841945,Treatment of Aggressive Localized Lymphoma,https://clinicaltrials.gov/study/NCT00841945,,TERMINATED,"Prospective and multicentric Phase III study, evaluation of the interest of the radiotherapy after 4 or 6 cycles of CHOP 14 R regimen of chemotherapy , patients with agressive and localized B lymphoma , age 18 to 75 years.",NO,B Cell Lymphoma,DRUG: rituximab|DRUG: doxorubicin|DRUG: vincristine|DRUG: prednisone|PROCEDURE: radiotherapy,"Event Free Survival (EFS) and Progression Free Survival (PFS), EFS PFS one year after treatment","Pet-scan, pronostic impact of Pet-scan|radiotherapy, Toxicity of the radiotherapy",,French Innovative Leukemia Organisation,,ALL,"ADULT, OLDER_ADULT",PHASE3,334,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,GOELAMS 02 03,2005-04,2016-01,2017-02,2009-02-12,,2017-02-23,"Regional university hospital, Rennes, 35033, France",
